Bora Pharmaceuticals acquires Eden Biologics CDMO Assets
Excerpt Bora announced that as part of its five-year growth plan, it will initially invest $50 million USD and up to $100 million USD in the acquisition of Eden Biologics’ CDMO assets in Taiwan. Article Summary Bora Pharmaceuticals, Taiwan’s leading international contract development and manufacturing company (CDMO), has just announced the establishment of Bora Biologics […]
Recipharm completes US biologics acquisitions
Excerpt: Recipharm, a leading global contract development and manufacturing organisation (CDMO), announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics. Article Summary Recipharm announced the acquisition of Arranta Bio and Vibalogics. With this acquisition, Recipharm strengthens its presence in the Biologics market, with a particular focus on drug […]
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022
Excerpt: Harbour BioMed announced a global out-license agreement with AstraZeneca for CLDN18.2xCD3 bispecific antibody (HBM7022), a novel bispecific antibody generated from HBM’s HCAb Based Immune Cell Engagers (HBICE®) Platform. Article Summary Harbour BioMed out-liscense agreement with AstraZeneca marks a major milestone in Harbour BioMed business development with the agreement and recognition by an industry-leading global […]
Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
Excerpt: FUJIFILM Corporation announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. for USD 100 million. Article Summary FUJIFILM has acquired the facility from Atara Biotherapeutics which is located in Thousand Oaks, California. It will be operated as part of FUJIFILM Diosynth Biotechnologies’ global network, which […]
Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe
Excerpt Catalent announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction near Oxford, U.K. Article Summary Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple […]
MGC Pharmaceuticals Enters Partnership with Sciensus Rare for Distribution of Cannabinoids to Treat Refractory Epilepsy, Dementia and Alzheimer’s in the EU and UK
Excerpt: MGC Pharmaceuticals Ltd. , a European based bio-pharma company specializing in the production and development of phytomedicines, has signed an exclusive distribution agreement with Sciensus Rare, a part of UK health care group, Sciensus, for the distribution of CannEpil® and CogniCann® in key European territories and the UK. Article Summary: The agreement is for […]
Aurobindo Pharma USA Increases Distribution Throughput and Performance with New Automated Warehouse System
Excerpt: When the generic pharmaceutical giant wanted to automate its U.S. nerve center, it sought an automated storage and retrieval system (ASRS) that boosted storage capacity by 450% and increased order fulfillment efficiency. Article Summary: India-based Aurobindo Pharma manufactures and distributes millions of generic pharmaceuticals to more than 150 countries, overseeing a complex, global operation […]
Real-Time In-Transit Visibility: Implications for the Pharma Cold Chain
Excerpt: Recent chaos and uncertainty make a strong use case for real-time, end-to-end visibility at scale in the pharma cold chain. Shippers of high-value urgent, fragile and perishable cargoes need continuous monitoring of shipment location, condition and security. They need to know, preferably in real time, when goods will not arrive on time and in […]
Samsung Biologics capitalises on pandemic boom to expand in US and Europe
Excerpt: South Korean group makes Covid-19 treatments for the UK’s GSK and AstraZeneca Article Summary: Samsung Biologics, the biopharmaceutical unit of South Korea’s Samsung Group, is seeking to build its first plants in the US and Europe as it rebalances its global supply chains following the pandemic. The world’s largest contract drugmaker, which produces for […]
Singapore and Asia’s leading BioPharma Map the Future and Catalyze Recovery for the Biomanufacturing Industry
Singapore, 31st March 2022 – The 9th Annual Biologics Manufacturing Asia 2022 & the 6th Annual BioLogistics World Asia 2022 conferences kicks off with Industry views on post pandemic biomanufacturing and a focus on the future of Asia’s Bioprocessing sector. The annual event gathered biologics and vaccine experts from all over the world at Suntec […]
AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate (Clone)
Excerpt AGC Biologics announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility as a part to fight the pandemic variants. Article Summary AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced partnership with Pfizer-BioNTech to provide more plasmid […]
Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Excerpt Biocon Biologics Limited’s (BBL) acquisition of Viatris’ rights in biosimilars assets making BBL a unique global, vertically integrated biosimilars leader. This transaction accelerates BBL’s direct commercialization strategy for its current and future biosimilars portfolio. Article Summary Biocon Biologics Ltd., a subsidiary of Biocon Ltd. announced today that it has entered into a definitive agreement […]
